作者
Vinay Chandrasekhara, Mouen A Khashab, V Raman Muthusamy, Ruben D Acosta, Deepak Agrawal, David H Bruining, Mohamad A Eloubeidi, Robert D Fanelli, Ashley L Faulx, Suryakanth R Gurudu, Shivangi Kothari, Jenifer R Lightdale, Bashar J Qumseya, Aasma Shaukat, Amy Wang, Sachin B Wani, Julie Yang, John M DeWitt
发表日期
2017/1/1
来源
Gastrointestinal endoscopy
卷号
85
期号
1
页码范围
32-47
出版商
Elsevier
简介
Post-ERCP pancreatitis (PEP) is the most common serious adverse event attributed to the procedure, resulting in annual estimated costs exceeding 150 million dollars in the United States. 2, 3 Controversy exists on how PEP should be defined. Elevated serum pancreatic enzyme levels alone do not constitute PEP, because transient increases in serum pancreatic enzyme levels may occur in up to 75% of individuals after the procedure, regardless of symptoms. 4 Conversely, individuals with low serum amylase levels less than 1.5 times the upper limit of
学术搜索中的文章
V Chandrasekhara, MA Khashab, VR Muthusamy… - Gastrointestinal endoscopy, 2017